Konica Minolta, Inc. announced the launch of Konica Minolta Precision Medicine Japan, Inc. (KMPMJ) which will start operations on October 1, 2018. KMPMJ is a 100%-owned subsidiary of Konica Minolta with responsibility for marketing high-end precision medicine tools and diagnostic services in Japan. The launch of KMPMJ is the latest development in Konica Minolta's ambitious goal of transforming personalized medicine. Building on its own world-class capabilities in medical imaging and software as well as its proprietary protein quantification technology, High Sensitivity Tissue Testing (“HSTT”)2, Konica Minolta announced its intentions to revolutionize personalized patient care in 2017 with the acquisitions of Ambry Genetics, Corporation (“Ambry”), a top American genetic testing and analysis firm, and Invicro, LLC. Combining the synergistic technologies of these three companies, KMPMJ addresses an unmet need in modern healthcare for reliable, standardized, and integrated technologies that support every aspect of translational medicine. Currently, biopharmaceutical companies and research institutes must piece together technologies from different sources to conduct translational research, which can lead to inefficiencies, inaccuracies or quality control issues.



KMPMJ will be led by president Ken Masuo, a seasoned marketing executive with over 30 years of experience in the pharmaceutical industry, and will be based in Tokyo with 23 employees. KMPMJ will provide tools to identify and track disease-linked biomarkers1 and related services to accelerate the development of targeted therapies. It will also offer diagnostic and prognostic testing services using genes, proteins, and other molecules that increase physicians' ability to assess and treat their patients' disease.